Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipragliflozin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 known ✓ | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipragliflozin SCHEMBL27177473 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL18573706 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL17034641 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL903239 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL23731432 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL29433938 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL24037936 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL29358545 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL11971945 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL9908293 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240100071-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2024-03-28 | — | — | US | claimed |
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | INCREVET, INC. | 2023-01-05 | — | — | US | claimed |
| EP-4023218-A1 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-Form Pharma (BE) | 2022-07-06 | — | — | EP | claimed |
| WO-2022117893-A2 | COMBINATION THERAPY FOR PATIENTS HAVING ACUTE AND/OR PERSISTENT DYSPNEA | S-FORM PHARMA (BE) | 2022-06-09 | — | — | WO | claimed |
| US-20180016290-A1 | PROCESS FOR THE PREPARATION OF SGLT INHIBITOR COMPOUNDS | INDOCO REMEDIES LIMITED (IN) | 2018-01-18 | — | — | US | claimed |
| EP-3256482-A1 | PROCESS FOR THE PREPARATION OF SGLT INHIBITOR COMPOUNDS | Indoco Remedies Limited (IN) | 2017-12-20 | — | — | EP | claimed |
| US-20160346288-A1 | 1-[(3-CYANO-PYRIDIN-2-YL)METHYL]-3-METHYL-7-(2-BUTYN-1-YL)-8-[3-(R)-AMINO-PIPERIDIN-1-YL]-XANTHINE FOR THE TREATMENT OF A METABOLIC DISORDER OF A PREDOMINANTLY CARNIVOROUS NON-HUMAN ANIMAL | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2016-12-01 | — | — | US | claimed |
| WO-2016128995-A1 | PROCESS FOR THE PREPARATION OF SGLT INHIBITOR COMPOUNDS | INDOCO REMEDIES LIMITED (IN) | 2016-08-18 | — | — | WO | claimed |
| EP-1609785-B1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC (JP) | 2016-02-03 | — | — | EP | claimed |
| EP-2236137-B1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF FATTY LIVER DISEASES | ASTELLAS PHARMA INC (JP) | 2015-06-24 | — | — | EP | claimed |
| US-20110237532-A1 | 1-[(3-CYANO-PYRIDIN-2-YL)METHYL]-3-METHYL-7-(2-BUTYN-1-YL)-8-[3-(R)-AMINO-PIPERIDIN-1-YL]-XANTHINE FOR THE TREATMENT OF A METABOLIC DISORDER OF A PREDOMINANTLY CARNIVOROUS NON-HUMAN ANIMAL | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2011-09-29 | — | — | US | claimed |
| EP-2368552-A1 | 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal | Boehringer Ingelheim Vetmedica GmbH (DE) | 2011-09-28 | — | — | EP | claimed |
| US-7977466-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-12 | — | — | US | claimed |
| US-20110098240-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | US | claimed |
| US-20110077212-A1 | THERAPEUTIC USES OF SGLT2 INHIBITORS | THERACOS, INC. (US) | 2011-03-31 | — | — | US | claimed |
| US-20110003757-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING FATTY LIVER DISEASE | ASTELLAS PHARMA INC. (JP) | 2011-01-06 | — | — | US | claimed |
| EP-2236137-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF FATTY LIVER DISEASES | Astellas Pharma Inc. (JP) | 2010-10-06 | — | — | EP | claimed |
| US-7772407-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-10 | — | — | US | claimed |
| US-20090143316-A1 | COCRYSTAL OF C-GLYCOSIDE DERIVATIVE AND L-PROLINE | ASTELLAS PHARMA INC. (JP) | 2009-06-04 | — | — | US | claimed |
| EP-2009010-A1 | COCRYSTAL OF C-GLYCOSIDE DERIVATIVE AND L-PROLINE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237532-A1 | 1-[(3-CYANO-PYRIDIN-2-YL)METHYL]-3-METHYL-7-(2-BUTYN-1-YL)-8-[3-(R)-AMINO-PIPERIDIN-1-YL]-XANTHINE FOR THE TREATMENT OF A METABOLIC DISORDER OF A PREDOMINANTLY CARNIVOROUS NON-HUMAN ANIMAL | PDXK, ABAT, GPR119 | SLC5A2 39/4885SLC5A1 6/4885SLC6A3 1693/4885 |
| US-20110003757-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING FATTY LIVER DISEASE | SLC5A1, SLC5A2, SLC10A1 | SLC5A2 2/4885SLC5A1 1/4885SLC6A3 2456/4885 |
| US-20160346288-A1 | 1-[(3-CYANO-PYRIDIN-2-YL)METHYL]-3-METHYL-7-(2-BUTYN-1-YL)-8-[3-(R)-AMINO-PIPERIDIN-1-YL]-XANTHINE FOR THE TREATMENT OF A METABOLIC DISORDER OF A PREDOMINANTLY CARNIVOROUS NON-HUMAN ANIMAL | GOT2, ABAT, SLC7A1 | SLC5A2 27/4885SLC5A1 6/4885SLC6A3 550/4885 |
| US-20110077212-A1 | THERAPEUTIC USES OF SGLT2 INHIBITORS | SLC5A2, SLC5A1, PPARG | SLC5A2 1/4885SLC5A1 2/4885SLC6A3 270/4885 |
| US-20110098240-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR | SLC5A1, SLC5A2, DPP4 | SLC5A2 2/4885SLC5A1 1/4885SLC6A3 97/4885 |
| US-20090143316-A1 | COCRYSTAL OF C-GLYCOSIDE DERIVATIVE AND L-PROLINE | SLC6A7, SLC5A1, UGGT1 | SLC5A2 9/4885SLC5A1 2/4885SLC6A3 674/4885 |
| US-20230000816-A1 | SODIUM-GLUCOSE LINKED TRANSPORTER INHIBITORS FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE, HYPERTENSION, AND HEART FAILURE IN COMPANION ANIMALS | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885SLC6A3 100/4885 |
| US-20180016290-A1 | PROCESS FOR THE PREPARATION OF SGLT INHIBITOR COMPOUNDS | SLC5A2, SLC5A1, SLC2A9 | SLC5A2 1/4885SLC5A1 2/4885SLC6A3 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.